TJP1 and hepatocellular carcinoma: found that miR-103 in serum and liver cancer cell culture supernatants of patients with hepatocellular carcinoma can increase endothelial cell permeability and inhibit the expression of endothelial cells VE-Cad, p120, and ZO-1, as well as p120-E-Cad signaling, thereby attenuating endothelial cell junctions and promoting cancer cell migration (37).